⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

Official Title: A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG908 in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors

Study ID: NCT05275478

Interventions

TNG908

Study Description

Brief Summary: This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG908, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 192 participants.

Detailed Description: This is a Phase 1/2 multi-center, open label study in solid tumor patients (including glioblastoma) who have a confirmed homozygous MTAP deletion in their tumor. The Phase 1 portion is a dose escalation study of oral TNG908 in patients with confirmed MTAP-deleted solid tumors. In Phase 2, 6 expansion arms defined by confirmed MTAP-deleted tumor types will enroll in parallel at the RP2D of TNG908. In both parts of the study participants who tolerate the drug may continue treatment until disease progression.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

University of California Los Angeles, Los Angeles, California, United States

University of California San Francisco, San Francisco, California, United States

Northwestern University, Chicago, Illinois, United States

Massachusetts General Hospital, Boston, Massachusetts, United States

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Washington University, Saint Louis, Missouri, United States

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Sarah Cannon Tennessee Oncology, Nashville, Tennessee, United States

The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

NEXT Oncology, Fairfax, Virginia, United States

Centre Léon Bérard, Lyon, , France

EDOG Institut de Cancerologie de l'Ouest, Saint-Herblain, , France

Institute Gustav Roussy, Villejuif, , France

Contact Details

Name: Ellen Hooper, MD

Affiliation: Tango Therapeutics, Inc.

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: